Brief: RenovoRx CEO Issues Letter to Shareholders
06/02/2024 14:24
Feb 6 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX: RECENT FINANCING WILL DRIVE CO TOWARDS SECOND
INTERIM
ANALYSIS ON PIVOTAL PHASE III TIGER-PAC CLINICAL TRIAL BY END OF
2024
Source text for Eikon: ID:nBw6yrmtXa
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies